Table 4 Summary of our results and relevant clinical trials for mCRC
Study/first author | Phase | Treatment | Country | n | ECOG PSa | Age (median) | RR | PFS (month) | OS (month) | Neuropathy (G3/4) | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|
XELOX | |||||||||||
Cassidy J | 2 | XELOX | 6 European, Canada | 96 | 0–1 | 34–79 (64) | 55 % | 7.7 | 19.5 | 17 % | 12 |
TREE-1 Hochster HS | 2 | mFOLFOX6 vs FOL vs XELOX | United States | 150 | 0–1 | 31–84 (62) | 41 % vs 20 % vs 27 % | 8.7 vs 6.9 vs 5.9 | 19.2 vs 17.9 vs 17.2 | 18 % vs 10 % vs 21 % | 33 |
Ducreux M | 3 | XELOX vs FOLFOX6 | France | 306 | 0–2 | 32–84 (65) | 42 % vs 46 % | 8.9 vs 9.3 | 20.1 vs 18.9 | 11.0 % vs 25.5 % | 15 |
BEV | |||||||||||
AVF2107g Hurwitz H | 3 | IFL vs IFL + Bev | United States, Australia, New Zealand | 813 | 0–1 | 18–(59) | 35 % vs 45 % | 6.2 vs 10.6 | 15.6 vs 20.3 | - | 17 |
E3200 Giantonio BJ | 3 | FOLFOX4 vs FOLFOX4 + BEV vs BEV | United States, South Africa | 829 | 0–2 | 21–85 (61) | 8.6 % vs 22.7 % vs 3.3 % | 4.7 vs 7.3 vs 2.7 | - | 9.2 % vs 16.3 % vs 0.8 % | 18 |
FIRE-3 Heinemann V | 3 | FOLFIRI + cetuximab vs FOLFIRI + BEV | Germany, Austria | 592 | 0–2 | 27–79 (65) | 62 % vs 58 % | 10.0 vs 10.3 | 28.7 vs 25.0 | 0.7 % vs 1.4 % | 4 |
CALGB/SWOG 80405b | 3 | FOLFIRI or mFOLFOX6 + cetuximab vs FOLFIRI or mFOLFOX6 + BEV | United States | 1137 | 0–1 | 20–89 (59) | - | 10.5 vs 10.8 | 29.9 vs 29.0 | 12 % vs 14 % | 5 |
XELOX + BEV | |||||||||||
Wong NS | 2 | XELOX + BEV | United States | 50 | 0–2 | 24–81 (55) | 50 % | 10.3 | 23.3 | 14 % | 11 |
TREE-2 Hochster HS | 2 | mFOLFOX6 + BEV vs FOL + BEV vs XELOX + BEV | United States | 223 | 0–1 | 30–85 (61) | 52 % vs 39 % vs 46 % | 9.9 vs 8.3 vs 10.3 | 26.1 vs 20.4 vs 24.6 | 11 % vs 9 % vs 11 % | 33 |
16966 trial Saltz LB | 3 | FOLFOX4/XELOX vs FOLFOX4/XELOX + BEV | Worldwide | 1401 | 0–1 | 18–86 (60) | 38 % vs 38 % | 8.0 vs 9.4 | 19.9 vs 21.3 | - | 27 |
Elderly | |||||||||||
ASCA trial Munemoto Y | 2 | XELOX + BEV | Japan | 36 | 0.–1 | 75–86 (78) | 56 % | 11.7 | 22.9 | 13.9 % | - |
SGOSG-CR0501 Matsumoto T | 2 | UFT + LV | Japan | 21 | 0–2 | 75–83 (79) | 33 % | 5.3 | 18 | 0 % | 21 |
Feliu J | 2 | Capecitabine + BEV | Spain | 59 | 0–2 | 73–79 (75) | 34 % | 10.8 | 18.0 | 0 % | 24 |
Feliu J | 2 | XELOX | Spain | 54 | 0–2 | 70–82 (76) | 36 % | 5.8 | 13.2 | 2 % | 25 |
BECOX Feliu J | 2 | XELOX + BEV | Spain | 69 | 0–1 | 70–85 (75) | 31 % | 11.1 | 20.4 | 4 % | 28 |
BASIC trial Yoshida M | 2 | S-1 + BEV | Japan | 56 | 0–1 | 66–85 (75) | 57 % | 9.9 | 25.0 | 0 % | 26 |
AVEX Cunningham D | 3 | Capecitabine vs capecitabine + BEV | Worldwide | 280 | 0–2 | 70–87 (76) | 10 % vs 19 % | 5.1 vs 9.1 | 16.8 vs 20.7 | 0 % | 22 |
FOCUS2 Seymour MT | 3 | FL vs OxFU vs Capecitabine vs XELOX | United Kingdom | 459 | 0–2 | 35–87 (74) | 11 % vs 38 % vs 14 % vs 32 % | 3.5 vs 5.8 vs 5.2 vs 5.8 | 10.1 vs 10.7 vs 11.0 vs 12.4 | 0 % vs 1 % vs 0 % vs 4 % | 23 |